| Application no. and date | 15727470.5 (espacenet) (Federated) (European Patent Register), 20150527 | | Patent/reg. no. and date | DK/EP 3148513, 20200226 | | Publication date | 20170405 | | Priority no. and date | US 201462004359 P, 20140529 | | EP pub. no. and date |
EP 3148513 20170405 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | BTGP/160667 | | Inventor | BREULLES, Sebastien, c/o Novartis Pharma AG
Postfach
4002 Basel, CH,
ENSSLIN, Simon, c/o Novartis Pharma AG
Postfach
4002 Basel, CH | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61K 31/435 (2006.01) , A61K 31/506 (2006.01) , A61K 9/16 (2006.01) , A61K 9/20 (2006.01) | | Title | Ceritinib-formulering | | Int. application no. | IB2015053966 | | Int. publication no. | WO2015181739 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
